Bionic immunoactivator copresenting autophagy promoting and costimulatory molecules for synergistic cancer immunotherapy

[1]  D. Wheeler,et al.  Active recruitment of anti–PD-1–conjugated platelets through tumor-selective thrombosis for enhanced anticancer immunotherapy , 2023, Science advances.

[2]  Charles H. Yoon,et al.  An activation to memory differentiation trajectory of tumor-infiltrating lymphocytes informs metastatic melanoma outcomes. , 2022, Cancer cell.

[3]  Quanyin Hu,et al.  Depletion of tumor associated macrophages enhances local and systemic platelet-mediated anti-PD-1 delivery for post-surgery tumor recurrence treatment , 2022, Nature Communications.

[4]  A. Korman,et al.  The foundations of immune checkpoint blockade and the ipilimumab approval decennial , 2021, Nature Reviews Drug Discovery.

[5]  Quanyin Hu,et al.  Engineered platelets: Advocates for tumor immunotherapy , 2021, Nano Today.

[6]  Shannon E. McCarthy,et al.  Quiescent cancer cells resist T cell attack by forming an immunosuppressive niche , 2021, Cell.

[7]  Quanyin Hu,et al.  Inhibition of post-surgery tumour recurrence via a hydrogel releasing CAR-T cells and anti-PDL1-conjugated platelets , 2021, Nature Biomedical Engineering.

[8]  D. Green,et al.  Autophagy in tumour immunity and therapy , 2021, Nature Reviews Cancer.

[9]  I. Wistuba,et al.  PD-L1 as a biomarker of response to immune-checkpoint inhibitors , 2021, Nature Reviews Clinical Oncology.

[10]  J. Massagué,et al.  Targeting metastatic cancer , 2021, Nature Medicine.

[11]  Chen Jiang,et al.  Postoperative cancer treatments: In-situ delivery system designed on demand. , 2020, Journal of controlled release : official journal of the Controlled Release Society.

[12]  K. Kwiatkowska,et al.  TLR4 and CD14 trafficking and its influence on LPS-induced pro-inflammatory signaling , 2020, Cellular and Molecular Life Sciences.

[13]  L. Del Mastro,et al.  New emerging targets in cancer immunotherapy: the role of GITR , 2020, ESMO open.

[14]  R. Deng,et al.  Autophagy deficiency promotes triple-negative breast cancer resistance to T cell-mediated cytotoxicity by blocking tenascin-C degradation , 2020, Nature Communications.

[15]  Shuhua Wei,et al.  Regulatory T cells in tumor microenvironment: new mechanisms, potential therapeutic strategies and future prospects , 2020, Molecular Cancer.

[16]  Man Li,et al.  On‐Demand Autophagy Cascade Amplification Nanoparticles Precisely Enhanced Oxaliplatin‐Induced Cancer Immunotherapy , 2020, Advanced materials.

[17]  H. Nakatogawa.  Mechanisms governing autophagosome biogenesis , 2020, Nature Reviews Molecular Cell Biology.

[18]  S. Sakaguchi,et al.  Regulatory T Cells and Human Disease. , 2020, Annual review of immunology.

[19]  Ying Zhu,et al.  Circulating tumor cells in cancer patients: developments and clinical applications for immunotherapy , 2020, Molecular Cancer.

[20]  Yao-Xin Lin,et al.  In Situ Manipulation of Dendritic Cells by an Autophagy-Regulative Nanoactivator Enables Effective Cancer Immunotherapy. , 2019, ACS nano.

[21]  D. Gozuacik,et al.  Autophagy as a molecular target for cancer treatment. , 2019, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[22]  R. Bell,et al.  Advances in drug delivery for post-surgical cancer treatment. , 2019, Biomaterials.

[23]  H. Shan,et al.  The relationship between autophagy and the immune system and its applications for tumor immunotherapy , 2019, Molecular Cancer.

[24]  Rachel S. Riley,et al.  Delivery technologies for cancer immunotherapy , 2019, Nature Reviews Drug Discovery.

[25]  N. Altorki,et al.  The lung microenvironment: an important regulator of tumour growth and metastasis , 2018, Nature Reviews Cancer.

[26]  R. Shaw,et al.  Autophagy in Cancer: Regulation by Small Molecules. , 2018, Trends in pharmacological sciences.

[27]  J. Heemskerk,et al.  Platelet biology and functions: new concepts and clinical perspectives , 2018, Nature Reviews Cardiology.

[28]  Quanyin Hu,et al.  Conjugation of haematopoietic stem cells and platelets decorated with anti-PD-1 antibodies augments anti-leukaemia efficacy , 2018, Nature Biomedical Engineering.

[29]  M. Schlesinger.  Role of platelets and platelet receptors in cancer metastasis , 2018, Journal of Hematology & Oncology.

[30]  Quanyin Hu,et al.  Engineering PD-1-Presenting Platelets for Cancer Immunotherapy. , 2018, Nano letters.

[31]  Shampa Chatterjee,et al.  Endothelial Mechanotransduction, Redox Signaling and the Regulation of Vascular Inflammatory Pathways , 2018, Front. Physiol..

[32]  R. Weinberg,et al.  Understanding the tumor immune microenvironment (TIME) for effective therapy , 2018, Nature Medicine.

[33]  J. Kailashiya.  Platelet-derived microparticles analysis: Techniques, challenges and recommendations. , 2018, Analytical biochemistry.

[34]  D. Gabrilovich,et al.  Myeloid-derived suppressor cells coming of age , 2018, Nature Immunology.

[35]  Zhen Gu,et al.  In situ activation of platelets with checkpoint inhibitors for post-surgical cancer immunotherapy , 2017, Nature Biomedical Engineering.

[36]  J. Liesveld,et al.  Genetic engineering of platelets to neutralize circulating tumor cells. , 2016, Journal of controlled release : official journal of the Controlled Release Society.

[37]  M. Mihm,et al.  Tumour-infiltrating lymphocytes in melanoma prognosis and cancer immunotherapy. , 2016, Pathology.

[38]  T. Saitoh,et al.  Autophagy and autophagy-related proteins in the immune system , 2015, Nature Immunology.

[39]  B. Kwon,et al.  Glucocorticoid-induced tumor necrosis factor receptor–related protein co-stimulation facilitates tumor regression by inducing IL-9–producing helper T cells , 2015, Nature Medicine.

[40]  A. Franco,et al.  Platelets at the interface of thrombosis, inflammation, and cancer. , 2015, Blood.

[41]  C. Münz,et al.  Checking the garbage bin for problems in the house, or how autophagy assists in antigen presentation to the immune system. , 2013, Seminars in cancer biology.

[42]  M. Knittler,et al.  Amphisomal Route of MHC Class I Cross-Presentation in Bacteria-Infected Dendritic Cells , 2013, The Journal of Immunology.

[43]  D. Rubinsztein,et al.  Autophagy modulation as a potential therapeutic target for diverse diseases , 2012, Nature Reviews Drug Discovery.

[44]  Daniel A. Heller,et al.  Treating metastatic cancer with nanotechnology , 2011, Nature Reviews Cancer.

[45]  F. Di Virgilio,et al.  Autophagy-Dependent Anticancer Immune Responses Induced by Chemotherapeutic Agents in Mice , 2011, Science.

[46]  J. Freedman,et al.  Platelets and the immune continuum , 2011, Nature Reviews Immunology.

[47]  Xiao-Ming Yin,et al.  Dissecting the dynamic turnover of GFP-LC3 in the autolysosome , 2011, Autophagy.

[48]  H. Virgin,et al.  Autophagy in immunity and inflammation , 2011, Nature.

[49]  D. Rubinsztein,et al.  Regulation of mammalian autophagy in physiology and pathophysiology. , 2010, Physiological reviews.

[50]  M. Croft.  Co-stimulatory members of the TNFR family: keys to effective T-cell immunity? , 2003, Nature Reviews Immunology.

[51]  M. Colombo,et al.  A novel assay to study autophagy: regulation of autophagosome vacuole size by amino acid deprivation. , 2001, Journal of cell science.

[52]  S. Heptinstall,et al.  Novel strategies for assessing platelet reactivity. , 2017, Future cardiology.

[53]  Pengcheng Bu,et al.  Targeted drug delivery to circulating tumor cells via platelet membrane-functionalized particles. , 2016, Biomaterials.

[54]  M. Pypaert,et al.  Antigen-loading compartments for major histocompatibility complex class II molecules continuously receive input from autophagosomes. , 2007, Immunity.